BACKGROUND: Evidence-based therapies for @entity308 , as described in the clinical guidelines, are based on results from randomised controlled trials (RCTs). So far, it is not known to what extent results of @entity308 can be generalised to 'real life' clinical practice.<br/> AIM: To compare treatment results for @entity308 from RCTs (efficacy) and results from daily practice (effectiveness); furthermore, to assess to what extent eligibility criteria and (un)intended selection by recruitment procedures influences treatment outcomes in daily practice.<br/> METHOD: In a 'real life' @entity1 population (n = 1653) suffering from @entity308 (established by the MINIplus) and assessed in routine outcome monitoring at baseline, we explored how many @entity1 met the eligibility criteria for antidepressant and psychotherapy efficacy trials. Furthermore we explored to what extent RCT @entity1 differed in socio-demographic and socio-economic status from 'daily practice' @entity1 . 626 of the @entity2172 @entity1 had at least one follow-up assessment. In this follow-up group we compared the treatment outcome (assessed by the MADRS and BDI-II) to the results of 15 meta-analyses of RCTs. We also explored to what extent @entity1 selection based on eligibility criteria and socio-demographic/socio-economic status influenced treatment outcome. <br/> RESULTS: Remission percentages (21-27% in @entity2172 versus 34-58% in RCTs) and effect sizes (0.85 in @entity2172 versus 1.71 in RCTs, within-group data) were lower in daily practice than in RCTs. @entity2172 @entity1 differed from RCT @entity1 in many disease-specific and socio-economic features. These differences are due to @entity1 selection in RCTs. However, the influence of @entity1 selection based on eligibility criteria and socio-demographic differences in treatment outcome were very modest (explained variances 1-11%).<br/> CONCLUSION: Treatment success for @entity308 is lower in daily practice than in RCTs and 'real life' @entity1 differ in many features from RCT @entity1 . However, these differences cannot explain the difference between efficacy and effectiveness. The generalisability of the results of @entity308 trials to daily practice might not be jeopardised by the use of eligibility criteria and recruitment procedures to the extent suggested in earlier research.

[The generalisability of XXXX trials to clinical practice].

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression', 'major depression', 'RCTs on major depression'] @entity2172 :: ('MESH:D010033', 'Disease') :: ['ROM']
@entity308 :: (MESH:D003866,Disease) :: ['depression']
